Overweight Impacts Histological Disease Activity of De Novo Metabolic Dysfunction‐Associated Steatotic Liver Disease After Liver Transplantation
Clinical Transplantation · 2024
DOI: 10.1111/ctr.70039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Alejandro Campos-Murguia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Liver Transplantation, Overweight, Postoperative Complications, Fatty Liver. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: PRACTIS-Clinician Scientist Program of Hannover Medical School, German Research Foundation, DAAD Research.
Abstract (Originalsprache)
Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a leading indication for liver transplantation (LT), but also occurs after LT. The prevalence of de novo MASLD (dnMASLD) after LT, based on both surveillance (svLbx) and indication biopsies (indLbx), is unknown. Furthermore, the impact of the distinct cardiometabolic risk factors on histological disease activity has not been assessed. We aimed to evaluate the prevalence of dnMASLD and the association between the cardiometabolic risk factors and histological disease activity.
Methods
We performed a retrospective single‐center study in a LT cohort with indLbx and svLbx. Patients with NAFLD before LT were excluded.
Results
We analyzed 249 patients who underwent either svLbx or indLbx. Forty‐eight (19.2%) had either dnMASLD ( n = 26/249, 10.4%) or metabolic dysfunction associated steatohepatitis (dnMASH) ( n = 22/249, 8.8%). Although dnMASLD/dnMASH was more frequent in indLbx (35.1%, p < 0.01), still 16.5% of patients with svLbx had dnMASLD/dnMASH. While overweight ( p < 0.01) and diabetes ( p = 0.01) were more frequent in patients with dnMASH, only overweight was associated with histological disease activity in the multivariate analysis. No impact of dnMASLD on the overall survival was observed.
Conclusion
While dnMASLD is more frequent in patients with indLBX, it also occurs in 16.5% of patients without signs of graft dysfunction. Overweight has the strongest impact on histological disease activity and should be monitored carefully after LT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
- Institut of Pathology, Hannover Medical School, Hannover, Germany.
- Ajmera Transplant Centre, Toronto General Hospital, United Health Network, University of Toronto, Toronto, Canada.
ORCID-Profile: Katharina Luise Hupa-Breier
Förderung
- PRACTIS-Clinician Scientist Program of Hannover Medical School
- German Research Foundation
- DAAD Research
- One-Year Grants for Doctoral Candidates
- German Academic Exchange Service
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Campos-Murguia, A., Guetzlaff, L., Bosselmann, E., Engel, B., Hartleben, B., Wedemeyer, H., Jaeckel, E., Taubert, R., & Hupa-Breier, K. L. (2024). Overweight Impacts Histological Disease Activity of De Novo Metabolic Dysfunction‐Associated Steatotic Liver Disease After Liver Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70039
Vancouver
Campos-Murguia A, Guetzlaff L, Bosselmann E, Engel B, Hartleben B, Wedemeyer H, et al. Overweight Impacts Histological Disease Activity of De Novo Metabolic Dysfunction‐Associated Steatotic Liver Disease After Liver Transplantation. Clinical Transplantation. 2024. doi:10.1111/ctr.70039
BibTeX
@article{CamposMurguia2024,
author = {Campos-Murguia, Alejandro and Guetzlaff, Lea and Bosselmann, Emily and Engel, Bastian and Hartleben, Björn and Wedemeyer, Heiner and Jaeckel, Elmar and Taubert, Richard and Hupa-Breier, Katharina Luise},
title = {Overweight Impacts Histological Disease Activity of De Novo Metabolic Dysfunction‐Associated Steatotic Liver Disease After Liver Transplantation},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.70039}
}
EUVIMED